Reprogramming Tumors; Bad Stool Samples; Human Experiences in Cancer Care

— News, features, and commentary about cancer-related issues

Onco Break over a computer rendering of a cancer cell.

A novel treatment that to make them more responsive to immunotherapy showed promising activity in a preliminary clinical study of triple-negative breast cancer. (Roswell Park Comprehensive Cancer Center, Journal for Immunotherapy of Cancer)

President Biden announced his , of Vanderbilt University Medical Center in Nashville, Tennessee, as the next National Cancer Institute director.

More than 10% of stool samples for routine were unsatisfactory for evaluation with fecal immunochemical testing. (American Association for Cancer Research)

Percutaneous ablation of lesions appeared safe and effective in a small multicenter clinical study. (American Journal of Roentgenology)

Adding the anti-PD-L1 antibody avelumab (Bavencio) to a novel targeted drug or radiation therapy did not improve , with the exception of a small group of patients with cervical cancer. (University of Texas MD Anderson Cancer Center, Cancer)

The MEK inhibitor mirdametinib produced objective responses in 52% of pediatric patients and 41% of adults with a specific type of , SpringWorks Therapeutics announced.

Pfizer and Astellas announced FDA expansion of enzalutamide (Xtandi) indications to include .

And Merck said the agency as first-line treatment for HER2-negative gastric or gastroesophageal junction cancer.

Journal of Clinical Oncology's Art of Oncology has published a special edition highlighting essays about .

Redispensing saves money and is good for the environment. (JAMA Oncology)

AI-derived models predicted the with 80% accuracy, better than currently available clinical models. (Catholic University of Rome, Nature Communications)

Highlighting , targeted drugs including CDK4/6 inhibitors just arrived in the African nation of Mozambique, almost a decade after the first drug in the class was approved in the U.S. (ABC GlobAlliance)

  • author['full_name']

    Charles Bankhead is senior editor for oncology and also covers urology, dermatology, and ophthalmology. He joined app in 2007.